Answers are grounded in this paper and cite their sources.
Shows NGR1 suppresses osteoclastogenesis in bone health, suggesting its potential as a therapeutic candidate.
This study provides the first comprehensive evidence that NGR1 acts as a multi-target regulator of osteoclastogenesis through NO-dependent mechanisms. By integrating the suppression of NO levels with predicted modulation of inflammatory, apoptotic, and signal transduction pathways, NGR1 suppresses osteoclast differentiation and function. These findings advance the molecular understanding of Panax notoginseng in bone health and support NGR1 as a promising therapeutic candidate for pathological bone loss, warranting further in vivo and translational investigation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: